A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Follow the latest news headlines from Australia's most trusted source. Read in-depth expert analysis and watch live coverage on ABC News.

Lenacapavir' was developed by Gilead Sciences, a research-based biopharmaceutical company in the US, as a pre-exposure prophylaxis (PrEP) medication to prevent infection in people at risk of exposure ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

COVID-19 took the lives of more than one million Americans and nearly 116,000 Californians, according to the Centers for Disease Control and Prevention.

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...